Curis Prices $5.6 Million Offering Of Shares And Warrants; Stock Up

Curis, Inc. (CRIS) priced a public offering with certain healthcare-focused institutional investors for 3.733 million shares or pre-funded warrants plus warrants. Combined price is $1.50 per share, with expected gross proceeds of about $5.6 million, closing around Aug. 14, 2026. Warrants exercise at $1.75, pre-funded warrants at $0.01. CRIS focuses on Emavusertib (CA-4948).

Original reporting
Published Aug 13, 2026, 3:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 3:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$CRIS
Bearish
medium confidence
Mentioned
$CRIS
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$CRISBearishMed
01

Why it matters

The company’s priced share-and-warrant offering provides incremental gross proceeds of about $5.6M but introduces dilution and potential warrant overhang, which can influence trading around the closing date.

02

Market read

This is a direct financing event with defined terms (price, share count, warrant exercise terms) that can drive short-term supply/dilution expectations.

03

What to watch

Warrant structure (immediate exercisability, $1.75 exercise price, five-year term) can affect future dilution timing and hedging demand, not just the headline share count.

Relevance 8/10Novelty 8/10Timing: offering priced, expected to close on or about Aug. 14, 2026

Background

Curis is developing Emavusertib (CA-4948) in TakeAim Lymphoma Phase 1/2 and TakeAim CLL Phase 2 studies.

Company-level read

Ticker impact

$CRISBearishMedium confidence
Context

Curis priced a public offering of 3.733M shares plus warrants, raising about $5.6M and closing around Aug. 14, 2026.

Expected impact

Near-term downside risk from dilution and overhang, with potential stabilization if investors view proceeds as funding for ongoing Phase 1/2 and Phase 2 studies.

Evidence & confidence

The article discloses the offering size, price ($1.50), warrant terms (exercise $1.75, pre-funded $0.01), and expected gross proceeds ($5.6M), which are direct inputs to dilution and financing risk.

Market effects

Biotech financing conditions and dilution risk remain a key driver for small-cap healthcare names, especially those running early-stage oncology trials.

No clear regional spillover beyond US micro/small-cap biotech sentiment.

Limited global impact; primarily affects Curis-specific capital structure and near-term trading flows.

Counterpoint

The stock being up after pricing suggests some investors may be treating the raise as supportive of trial continuity rather than purely dilutive.

Key entities

  • Curis, Inc.

    Priced a $5.6M public offering of common shares and accompanying warrants for Emavusertib development.

  • A.G.P./Alliance Global Partners

    Lead placement agent for the offering.

  • Laidlaw & Company (UK) Ltd.

    Co-placement agent for the offering.

Related articles

$CRISHigh

Curis Provides Third Quarter 2026 Business Update

CURIS INC (CRIS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE Curis Provides Third Quarter 2026 Business Update Management to host conference call and webcast today at 4:30 p.m. ET LEXINGTON, Mass., November 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of

$CRISMed

Curis (CRIS) Q3 2026 Earnings Call Transcript

Curis (CRIS) reported Q3 2026 net loss of $8.1M, narrower than 2025. The company is advancing clinical trials for emavusertib in NHL and CLL, with initial data expected by year-end. They aim for accelerated approval submissions in 2027. Cash reserves are $5M, expected to fund operations into 2027.

$CRISMedAI 8/10

Curis Provides Third Quarter 2026 Business Update

Curis, Inc. (CRIS) reported Q3 2026 financial results, showing a net loss of $8.1M, and provided a business update. The company is conducting studies on emavusertib for CLL and PCNSL, with initial data expected in December 2026. Curis completed a public offering and a private placement, extending its cash runway into 2027. Management will host a conference call to discuss the update.

$CRISMed

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus - Curis (NASDAQ:CRIS)

Curis (NASDAQ:CRIS) reported progress in clinical programs for its oral IRAK4 and FLT3 inhibitor targeting blood cancers. HC Wainwright said TakeAim CLL enrollment is ahead of plan, with year-end guidance raised to 5-10 patients, and reiterated a Buy rating while lifting its price target from $17 to $43. The note also updated emavusertib valuation assumptions and shifted PCNSL launch to 2029 and AML/MDS to 2032.

$CRISMedAI 8/10

Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates - Curis (NASDAQ:C

Curis Inc. (NASDAQ:CRIS) reported updated clinical results for emavusertib and expanded trial timeline guidance. In its TakeAim Primary CNS Lymphoma study, overall response was 100% (5/5) in BTK-naive evaluable patients and 86% (6/7) overall. BTK-experienced response was 26% (10/39). In TakeAim CLL, Curis added sites and raised its year-end data target to 5-10 patients in Dec 2026.

$CRISMedAI 8/10

Curis stock jumps 11% on positive emavusertib trial data By Investing.com

Curis, Inc. (NASDAQ:CRIS) shares rose about 11% after the company reported updated emavusertib clinical data in primary CNS lymphoma and raised enrollment guidance for its chronic lymphocytic leukemia study. In PCNSL, it cited an 86% overall response rate in BTK inhibitor-naïve and 26% in BTKi-experienced patients as of July 1, 2026. For CLL, it guided year-end enrollment to 5-10 patients.